Efficacy of generic sofosbuvir with daclatasvir compared to sofosbuvir/ledipasvir in genotype 4 hepatitis C virus: A prospective comparison with historical control.

Hala JoharjiDelal AlkortasAziza A AjlanMohamed AhmedHamad Al-AshgarMohammed Al-QuaizDieter BroeringMohammed Al-SebayelHussien ElsiesyFaisal A AlkhailWaleed K Al-HamoudiEdward De VolEpi Amirah AlmuhayshirAhmed Al-Jedai

Published in: Health science reports (2022)

Generic sofosbuvir combined with branded daclatasvir was safe and effective for treating genotype 4 HCV compared to Sof-Led. This combination may significantly reduce the cost burden, enabling a larger pool of treated patients. Office of research affairs at KFSHRC RAC# 2171 036.

Keyphrases

hepatitis c virus
human immunodeficiency virus
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
risk factors
patient reported